Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
therapy; crisis assessment and intervention; consultation, and outreach programming to the university community; supervision of doctoral interns and graduate trainees; and participation on divisional and
-
treatment strategies using biological therapeutics. Both the development of binding molecules and gene therapy vectors will be part of the project. In our research group, laboratory technicians, PhD students
-
that enable accurate and real-time diagnosis and therapies. Project background Polyethylene wear is a major factor affecting the long-term performance of hip implants, as it can lead to particle-induced
-
of Oncology Services and Cell/Gene Therapy and have a secondary reporting to the Chief Patient Care Services Officer in a matrixed reporting structure. This position is a critical member of the Oncology
-
. Epitranscriptomics is a new science field that studies RNA modifications (epitranscriptomic marks) and their function in regulation of gene expression. It is long known that many different RNA modifications exist. Yet
-
potential new therapies for neuroblastoma, a common pediatric cancer. Survival rates for children with high-risk neuroblastoma remain low, highlighting the urgent need for novel and effective treatments. Long
-
translational research center hosting several groups working in areas such as infection biology, immunology, and cell therapy. At CIM, research and development in NK cell biology and cell therapy is conducted
-
the Marie Skłodowska-Curie Actions (MSCA) programme, aims to explore strategies to develop stem cell therapies and biomaterials, laying the groundwork for future cures to restore eyesight. As one
-
of Coimbra, with the ambition of developing innovative platforms incorporating therapeutic agents (e.g., nucleic acids, small molecules, peptides), involving mRNA for gene therapy. In the context
-
small portion of the tumor. Once the diagnosis is made, few criteria are available to predict treatment efficacy. Cancer therapies increasingly rely on biological and morphological criteria